mechlorethamine
Trade name: mustargen
Approved
Mar 15, 1949
Mechlorethamine also known as mustine, brand name MUSTARGEN administered intravenously is the prototype anticancer chemotherapeutic drug, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. In 2013 was approved orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Mechlorethamine belongs to the group of nitrogen mustard alkylating agents. Alkylating agents work by three different mechanisms: attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations all of which achieve the same end result - disruption of DNA function and cell death. — NCATS
Clinical trial activity
24 trials · 48 clinical orgs · 3 marketing orgs
Earliest trial started Feb 1, 1989 (NCT00002463)
Timeline
Indications
Approved for
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Alkylating agent
Approval history
- approvedPriority reviewMar 15, 1949
Chemistry & pharmacology
SMILES
CN(CCCl)CCCl- Mol. weight
- 156.06 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL427 ↗
- WikipediaChlormethine ↗
- NCATS50D9XSG0VR ↗
- ChEMBLCHEMBL1201001 ↗
Also known as
- 2,2'-dichloro-n-methyldiethylamine
- 2,2'-dichloro-n-methyldiethylamine
- beta,beta'-dichlorodiethyl-n-methylamine
- beta,beta'-dichlorodiethyl-n-methylamine
- bis(2-chloroethyl)methylamine
- bis(2-chloroethyl)methylamine
- bis(beta-chloroethyl)methylamine
- bis(beta-chloroethyl)methylamine
- chlormethine
- chlormethine
- chlormethine
- chlormethine
- chlormethine
- hn2 hcl
- hn2 hcl
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine
- mechlorethamine hcl
- mechlorethamine hcl
- mechlorethamine hcl
- mechlorethamine hydrochloride
- mechlorethamine hydrochloride
- mechlorethamine hydrochloride
- mechlorethamine hydrochloride
- methylbis(2-chloroethyl)amine
- methylbis(2-chloroethyl)amine
- methylbis(beta-chloroethyl)amine
- methylbis(beta-chloroethyl)amine
- mustargen
- mustargen
- mustargen
- mustargen
- mustine
- mustine
- mustine
- nitrogen mustard
- nitrogen mustard
- nitrogen mustard
- nitrogen mustard
- nitrogen mustard n-oxide hcl
- n-methyl-bis(2-chloroethyl)amine
- n-methyl-bis(2-chloroethyl)amine
- n-methyl-bis(beta-chloroethyl)amine
- n-methyl-bis(beta-chloroethyl)amine
- tinefcon
- valchlor
- valchlor
- β,β'-dichlorodiethyl-n-methylamine
- β,β'-dichlorodiethyl-n-methylamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06149247 | Phase 2 | Dec 5, 2023 | Soligenix |
| NCT05303480 | N/A | Dec 7, 2021 | Leiden University, Recordati |
| NCT04218825 | Phase 2 | Jul 31, 2020 | European Organisation for Research and Treatment of Cancer, University of Birmingham, University of Lausanne |
| NCT04026269 | Phase 1/Phase 2 (Phase 2) | Jul 30, 2019 | People's Liberation Army of China |
| NCT03288818 | Phase 2 | Aug 31, 2018 | Actelion, Thomas Jefferson University |
| NCT03417141 | Phase 2 | Apr 1, 2018 | Actelion, Mayo Clinic |
| NCT03380026 | Phase 2 | Dec 13, 2017 | Rochester Skin Lymphoma Medical Group, PLLC, University of Rochester |
| NCT02968446 | Early Phase 1 (Phase 1) | Nov 17, 2016 | Case Western Reserve University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) |
| NCT02881749 | Phase 2 | Sep 1, 2016 | Actelion, Thomas Jefferson University |
| NCT01373567 | Phase 4 | Dec 1, 2010 | Bhatia Skin Center, Bima Nagar, Indore, Dr. D. Y. Patil Dental College & Hospital, Dr. Saple's clinic, 88, 3rd Lane, Hindu Colony, Near Bhagini Samaj, Dadar (East), Mumbai-400014, Durgabai Deshmukh Hospital & Research Center, Lokmanya Tilak Municipal Medical College, Medipoint Hospitals Pvt. Ltd., M.S. Diabetes and Shirdi Skin care centre 6/1, 80 Feet Road, Opp. Krishna Sagar Hotel, Indiranagar, Bangalore, Navprabhat Chambers,Opp, Nagpur, NKP Salve Institute and Lata Mangeshkar Hospital, Nagpur, Piramal, Postgraduate Institute of Medical Education and Research, PSG Hospital, Peelamedu, Rajiv Gandhi University of Health Sciences, Renova Skin & Laser Clinic, Jaipur, Sai Life Sciences, Sheth VS General Hospital, Skin Care Clinic, Nagpur, Skin & Laser Center, New Delhi, Sri Skin Care & Laser Clinic, Chowk-Lucknow, Swarnkar Superspeciality Centre,84,Shreenagar Main,Regency Avenue,Ground Floor, Near Anand Bazar,Indore |
| NCT00846742 | Phase 2 | Jun 5, 2009 | St. Jude Children's Hospital |
| NCT00574496 | Phase 2 | Nov 1, 2007 | Cornell University, National Cancer Institute (NCI) |
| NCT00535470 | Phase 2 | Jul 1, 2007 | Ceptaris, Temple University |
| NCT00352027 | Phase 2 | Jul 1, 2006 | St. Jude Children's Hospital |
| NCT00168064 | Phase 2 | May 1, 2006 | Ceptaris, Temple University |
| NCT00041210 | Phase 3 | Oct 1, 2001 | Inova Health System |
| NCT00145600 | Phase 2 | Mar 1, 2000 | St. Jude Children's Hospital |
| NCT00003389 | Phase 3 | Apr 1, 1999 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Stanford University |
| NCT00003262 | Phase 2 | May 1, 1997 | Centro di Riferimento Oncologico - Aviano |
| NCT00002714 | Phase 2 | Apr 1, 1995 | National Cancer Institute (NCI), Stanford University |